ClinicalTrials.gg
Active, not recruitingNCT07497412ANDANTE-REDSUpdated Mar 27, 2026

The Effect of Continuous Positive Airway Therapy on the Blood Pressure in Sleepy vs Non-sleepy Patients With Obstructive Sleep Apnea

An observational study in Obstructive Sleep Apnea, sponsored by King's College London. Active, not recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by King's College London · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Other
Enrollment
10,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 54 studies in Sleep Apnea, Obstructive with a site in United Kingdom — 9 open to participants now, 13 under way, none of them phase 3. Sleep Apnea, Obstructive · United Kingdom.

Planned enrollment
Largest of 28
10,000 · median 102
Started
2026
with 2 others
Observational
28 of 54
6 open now
Primary completion
2026-11
later than 8 of 12 live
Registered
54th of 54
by date
Lead sponsor
5 of 54
King's College London

Among the 54 studies in Sleep Apnea, Obstructive with a site in United Kingdom, this one has the largest planned enrollment of the 28 observational ones that give a count, is one of 3 that started in 2026, is one of 28 observational ones, reaches primary completion later than 8 of the 12 other live ones, and was the 54th registered.

Sleep Apnea, Obstructive

2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

9 of the 54 studies in Sleep Apnea, Obstructive with a site in United Kingdom are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Sleep Apnea, Obstructive with a site in United Kingdom, or all of them as a file.
02

Study summary

Obstructive sleep apnoea (OSA) is one of the most common noncommunicable types of disease, it affects about 1 billion people across the world. Left untreated, it causes apnoeas and hypopnoeas to fragment sleep, with frequent arousal from sleep and intermittent hypoxia associated with increased work of breathing. Frequently, it leads to excessive daytime sleepiness, as measured subjectively by the Epworth Sleepiness Scale, or, objectively, by the multiple sleep latency test (MSLT) or the maintenance of wakefulness test (MWT). OSA can lead to sustained high sympathetic tone at night, which in the long-term may impact on the cardiovascular risk.

The investigators hypothesised that any primary airway therapeutic effect on the cardiovascular system, as measured by the blood pressure, in patients with OSA will differ dependent on whether subjects are excessively sleepy, or remain so when treated.

Hypothesis

  1. Office blood pressure (SBP, DBP) responses to CPAP in patients with OSA who are excessively sleepy (ESS>10) at baseline vs non-sleepy patients at baseline.
  2. 24-hour BP data (SBP, DBP, dipping, nocturnal and daytime) in sleepy patients in response to CPAP vs non-sleepy patients.
  3. Adherence to treatment in sleepy patients may be different to non-sleepy patients and the observed effect effects will be adjusted in a secondary analysis according to available adherence data and follow up time.
Read the detailed description

Introduction

Obstructive sleep apnoea (OSA) is one of the most common noncommunicable types of disease, it affects about 1 billion people across the world. Left untreated, it causes apnoeas and hypopnoeas to fragment sleep, with frequent arousal from sleep and intermittent hypoxia associated with increased work of breathing. Frequently, it leads to excessive daytime sleepiness, as measured subjectively by the Epworth Sleepiness Scale, or, objectively, by the multiple sleep latency test (MSLT) or the maintenance of wakefulness test (MWT). OSA can lead to sustained high sympathetic tone at night, which in the long-term may impact on the cardiovascular risk.

With optimised primary airway treatment, normal breathing at night resumes and patients experience a restoration of normal sleep architecture, with little or no further sleep fragmentation due to the underlying sleep disordered breathing. Daytime symptoms and quality of life typically improve with primary airway treatment, and long-term cardiovascular risks follows.

Data from the ANDANTE collaboration have recently shown that the effect of primary airway patency treatment in patients with obstructive sleep apnoea on the blood pressure control differs according to whether patients with OSA have normal blood pressure, controlled or uncontrolled hypertension. Furthermore, the high prevalence of OSA in the general population, frequently diagnosed randomly (e.g., screening prior to elective surgery) in otherwise asymptomatic patients raises the question whether symptoms, like sleepiness, that are associated with the syndrome predict outcomes on the cardiovascular system.

There are clinically relevant implications in who should and who should not be treated with OSA, particularly in the cohort of mild/moderate and asymptomatic patients with OSA, as recently discussed in the Baveno, and the modified Baveno classification. Furthermore, a proportion of patients with OSA who are adherent to primary airway therapy remain symptomatic, as measured by the Epworth Sleepiness Scale, a phenomenon that has been labelled residual excessive daytime sleepiness. The cardiovascular risk associated with patients who are excessively sleepy at baseline, and who remain so, is unclear.

The investigators hypothesised that any primary airway therapeutic effect on the cardiovascular system, as measured by the blood pressure, in patients with OSA will differ dependent on whether subjects are excessively sleepy, or remain so when treated.

Hypothesis

  1. Office blood pressure (SBP, DBP) responses to CPAP in patients with OSA who are excessively sleepy (ESS>10) at baseline vs non-sleepy patients at baseline.
  2. 24-hour BP data (SBP, DBP, dipping, nocturnal and daytime) in sleepy patients in response to CPAP vs non-sleepy patients.
  3. Adherence to treatment in sleepy patients may be different to non-sleepy patients and the observed effect effects will be adjusted in a secondary analysis according to available adherence data and follow up time.

The investigators expected that the ANDANTE dataset could be used to address the clinically relevant question whether primary airway therapy of sleepy/non-sleepy patients with OSA provides benefits for associated long-term cardiovascular risks, as measured by the blood pressure values and 24h modulation (dipping vs non dipping). These questions form an essential aspect when discussing therapeutic options with patients in the sleep department, particularly in asymptomatic patients with mild/moderate OSA.

Methods The purpose of this study was to retrospectively analyse the ANDANTE database using the individual patient data (IPD) from the recently published meta-analysis using the ANDANTE database, details of which have been published elsewhere (Pengo M et al, European Respiratory Journal 2025). The study was approved by the King's College London ethics committee (17/12/2025; MRA-25/26-53856) and, following peer-review, by the scientific committee of the ANDANTE collaboration (Application date: 17/12/2024).

The investigators sought to investigate the dataset by stratifying patients based on excessive sleepiness, defined as an Epworth Sleepiness Scale (ESS) score greater than 10 points (a) at baseline, and (b) at follow up.

Statistical Analysis Plan Data management

This study will retrospectively analyse the ANDANTE database using individual patient data (IPD) from the previously published meta-analysis (Pengo M et al, European Respiratory Journal 2025). As a first step, we will stratify patients based on the Epworth Sleepiness Scale (ESS) both at baseline and at follow-up, considering a threshold of 10 points. From this stratification, we will create multiple study groups from which we will evaluate our primary and secondary outcomes:

  1. Baseline excessively sleepy patients (ESS >10).
  2. Baseline non-sleepy patients (ESS ≤10).

    1. Patients with residual sleepiness (maintained ESS>10 at follow-up).
    2. Patients with improved sleepiness (ESS reduced to ≤10). Blood pressure responses are described as office blood pressure measurement, 24h, diurnal / nocturnal SBP and DBP, and nocturnal dipping measurements at follow-up.

Primary Outcome The effect of baseline sleepiness classification (ESS > or ≤ 10) on the blood pressure response to CPAP treatment in patients with OSA (groups 1 vs 2).

Secondary Outcomes I) The effect of residual vs improving sleepiness on the blood pressure response to CPAP treatment in patients with OSA (groups a vs b).

II) Difference in adherence levels (measured by follow-up average daily use) between sleepy and non-sleepy patients at baseline and follow-up (groups 1 vs 2, and a vs b).

III) Effect of adherence in treatment responses (groups 1 vs 2, and a vs b).

Analytical Approach

1. Linear mixed models, predicting follow-up blood pressure measurements (dependent variables) by the above-described groups (ESS classifications), considering baseline blood pressure measurements and CPAP adherence as covariate, fixed effects.

  1. A set of models will be computed to assess effects of baseline classifications (groups 1 vs 2) and another set to assess differences at follow-up classifications (groups a vs b).
  2. These models will account for several random effects in time to follow-up, treatment site, age, gender, body mass index and comorbidities.

Statistical Reporting

  1. Baseline and follow-up data distributions will be presented as mean (standard deviation) for normally distributed data and median (interquartile range) for non-normally distributed data.
  2. Main results will be presented as the difference in follow-up blood pressure measurements between groups, accounting for baseline measurements, adherence and random effects. Adherence effects will be described as its coefficient of interaction with grouping in prediction.

Differences will be described as 95% confidence intervals and significance defined as p\<0.05.

03

Conditions studied

  • Obstructive Sleep Apnea

Keywords

  • cpap
  • continuous positive airway pressure
  • blood pressure
  • cardiovascular risk
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Adult patients with OSA who were randomised in an interventional trial to treat the condition using primary airway therapy (e.g., CPAP) in a randomised controlled trial (included in the ANDANTE database, Pengo M, Eur Resp J 2025)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Data for the individual patient data (IPD) meta-analysis, as published in the ANDANTE database (Pengo et al, European Respiratory Journal 2025)
  • Patient with OSA (apnoea hypopnea index, AHI > 5/hour)
  • age > 18 years
  • previous inclusion in published randomised controlled trial using primary airway therapy (intervention) or in the control arm

Exclusion criteria

Exclusion Criteria:

  • Not included in a randomised controlled trial to treat OSA
  • not included in the ANDANTE database
05

Study design

Observational model
Other
Time perspective
Other
Enrollment
10,000 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes

Groups and cohorts

  • Sleepy patients with OSA

    Patients with obstructive sleep apnea who are excessively sleepy, as measured by the Epworth Sleepiness Scale (ESS) \> 10 points

    Device: Primary airway therapy (e.g., CPAP) · Other: Control arm

  • Non-sleepy patients with OSA

    Patients with obstructive sleep apnea who are not excessively sleepy, as measured by the Epworth Sleepiness Scale (ESS) \<= 10 points

    Device: Primary airway therapy (e.g., CPAP) · Other: Control arm

Interventions

  • DevicePrimary airway therapy (e.g., CPAP)

    Treatment to restore upper airway patency in the asleep patient with OSA (e.g., CPAP)

  • OtherControl arm

    Control arm included in the randomised controlled trials of the ANDANTE database

06

What researchers measure

Primary outcomes

  1. Office blood pressure

    Office blood pressure measurements (systolic, diastolic in mmHg)

    Time frame: through study completion, an average of 3months

Secondary outcomes

  1. 24 hours blood pressure

    average systolic and diastolic blood pressure over 24 hours (mmHg)

    Time frame: through study completion, an average of 3months

  2. Nocturnal blood pressure dipping pattern

    Drop in nocturnal blood pressure (yes / no; \>10% compared to daytime BP)

    Time frame: through study completion, an average of 3months

Other outcomes

  1. Change in Epworth Sleepiness Scale associated with blood pressure changes (office, systolic / diastolic); minimal score 0, maximal score 24 points; higher scores indicate more severe sleepiness

    Change in ESS (points out of 24) from baseline to follow up and associated change in blood pressure (mmHg)

    Time frame: through study completion, an average of 3months

  2. Adherence to treatment

    Usage of CPAP therapy (hours per night)

    Time frame: through study completion, an average of 3months

07

Study locations

1 site
08

References and documents

Publications

  • Pengo MF, Schwarz EI, Barbe F, Cistulli PA, Drager LF, Fava C, Fuchs FD, Ip MSM, Loffler KA, Lui MMS, Martinez-Garcia MA, McEvoy D, Peker Y, Phillips CL, Quinnell T, Soranna D, Steier J, Stradling JR, Zambon A, Parati G; ANDANTE collaborators. Effect of CPAP therapy on blood pressure in patients with obstructive sleep apnoea: a worldwide individual patient data meta-analysis. Eur Respir J. 2025 Jan 2;65(1):2400837. doi: 10.1183/13993003.00837-2024. Print 2025 Jan. PubMed 39401854 ↗

Individual participant data

Plan to share: No — The ANDANTE database is an established open access registry in Milan / Italy and researchers can apply with the University of Milan-Bocca to access these data.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Nov 2026, 10 months after the start.

Of 258 non-industry observational studies under Sleep Apnea, Obstructive, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 63. This study's planned 10 months is below that.

Counting every sponsor, half of 294 studies reached it within 29 months; a quarter within 14 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2026
First posted
Mar 27, 2026
StartActual
Jan 1, 2026
Primary completionEst.
Nov 2026
CompletionEst.
Jun 2027
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07497412
Collaborators
University of Milan-Bocca, University of Grenoble-Alpes, Guy's and St Thomas' NHS Foundation Trust
Responsible party
Sponsor
First posted
Mar 27, 2026
Start date
Jan 1, 2026
Primary completion
Nov 2026 (estimated)
Completion
Jun 2027 (estimated)
Last update
Mar 27, 2026

Study contacts

Jean-Louis Pepin, PhD
study chair · University of Grenoble-Alpes
Carolina Lombardi, PhD
principal investigator · University of Milan-Bocca
Miquel Serna Pascual, PhD
principal investigator · King's College London
Antonella Zambon, PhD
study director · University of Milan-Bocca
Davide Soranna
principal investigator · University of Milan-Bocca
Joerg Steier, PhD
study chair · King's College London

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion